Abstract 2250
Background
Induction chemotherapy (ICT) followed by bioradiotherapy (BRT) is a validated conservative approach for fit LA-HNSCC patients (pts). However, in pts unfit for cisplatin-based chemotherapy, this treatment strategy remains a challenge. Paclitaxel in combination with anti-EGFR therapy is active and well-tolerated in the recurrent/metastatic setting. This study aims to evaluate this regimen as ICT followed by BRT.
Methods
A retrospective single institution analysis (2010-2016) of LA-HNSCC pts unfit for cisplatin-based chemotherapy (≥70 years-old and/or significant comorbidity) was performed. Pts were treated with paclitaxel plus anti-EGFR monoclonal antibody up to 9 weeks followed by radical BRT (IMRT with concurrent anti-EGFR therapy). Overall survival (OS) and progression free survival (PFS) were estimated by Kaplan-Meier method.
Results
A total of 44 pts were evaluated: median age 72 years-old (50-83), male 42; tumor location, pts (%): larynx 14 (32), oropharynx 10 (23) (HPV+ 0), hypopharynx 9 (21), oral cavity 7 (16), cervical unknown primary 4 (9); 7thed TNM stage, pts (%): EIII 11 (25), EIVa 19 (43) and EIVb 14 (32). ECOG status 0/1/2: 1/38/5 pts. Response rate to ICT: 32 pts (73%); 5 complete responses (CR) and 27 partial responses (PR). During ICT 5 pts (11%) presented grade 3/4 adverse events, and 1 patient (2%) died due to febrile neutropenia. 37 pts (84%) continued with radical BRT: 20 pts (45%) achieved CR, and 6 of them recurred. Median follow-up: 13.5 (1-52) months. For the whole cohort, median OS and PFS were 15.6 (95% CI 4.7-26.6) and 10.4 (95% CI 7.0-13.7) months, respectively. For the 35 pts who completed ≥6 weeks of ICT, median OS and PFS were 22.2 (95% IC 7.2-37.2) and 15.6 (95% IC 8.4-22.9) months, respectively. Larynx pts showed better outcome in comparison with other locations: median OS not reached (NR) vs 10.7 (p = 0.003) and median PFS NR vs 0 (p = 0.001); 9 pts (64%) preserved a functioning larynx and were alive by the time of the analysis.
Conclusions
Paclitaxel plus anti-EGFR therapy was well-tolerated and might be an effective ICT regimen for LA-HNSCC pts unfit for cisplatin. In our cohort, larynx pts obtained the greatest benefit from this regimen.
Clinical trial identification
Legal entity responsible for the study
Institut Catala de Oncologia.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract